Cargando…
Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border
BACKGROUND: Plasmodium vivax has a dormant hepatic stage, called the hypnozoite, which can cause relapse months after the initial attack. For 50 years, primaquine has been used as a hypnozoitocide to radically cure P. vivax infection, but major concerns remain regarding the side-effects of the drug...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988041/ https://www.ncbi.nlm.nih.gov/pubmed/21040545 http://dx.doi.org/10.1186/1475-2875-9-308 |
_version_ | 1782192215263543296 |
---|---|
author | Takeuchi, Rie Lawpoolsri, Saranath Imwong, Mallika Kobayashi, Jun Kaewkungwal, Jaranit Pukrittayakamee, Sasithon Puangsa-art, Supalap Thanyavanich, Nipon Maneeboonyang, Wanchai Day, Nicholas PJ Singhasivanon, Pratap |
author_facet | Takeuchi, Rie Lawpoolsri, Saranath Imwong, Mallika Kobayashi, Jun Kaewkungwal, Jaranit Pukrittayakamee, Sasithon Puangsa-art, Supalap Thanyavanich, Nipon Maneeboonyang, Wanchai Day, Nicholas PJ Singhasivanon, Pratap |
author_sort | Takeuchi, Rie |
collection | PubMed |
description | BACKGROUND: Plasmodium vivax has a dormant hepatic stage, called the hypnozoite, which can cause relapse months after the initial attack. For 50 years, primaquine has been used as a hypnozoitocide to radically cure P. vivax infection, but major concerns remain regarding the side-effects of the drug and adherence to the 14-day regimen. This study examined the effectiveness of using the directly-observed therapy (DOT) method for the radical treatment of P. vivax malaria infection, to prevent reappearance of the parasite within the 90-day follow-up period. Other potential risk factors for the reappearance of P. vivax were also explored. METHODS: A randomized trial was conducted from May 2007 to January 2009 in a low malaria transmission area along the Thai-Myanmar border. Patients aged ≥ 3 years diagnosed with P. vivax by microscopy, were recruited. All patients were treated with the national standard regimen of chloroquine for three days followed by primaquine for 14 days. Patients were randomized to receive DOT or self-administered therapy (SAT). All patients were followed for three months to check for any reappearance of P. vivax. RESULTS: Of the 216 patients enrolled, 109 were randomized to DOT and 107 to SAT. All patients recovered without serious adverse effects. The vivax reappearance rate was significantly lower in the DOT group than the SAT group (3.4/10,000 person-days vs. 13.5/10,000 person-days, p = 0.021). Factors related to the reappearance of vivax malaria included inadequate total primaquine dosage received (< 2.75 mg/kg), duration of fever ≤ 2 days before initiation of treatment, parasite count on admission ≥ 10,000/µl, multiple P. vivax-genotype infection, and presence of P. falciparum infection during the follow-up period. CONCLUSIONS: Adherence to the 14-day primaquine regimen is important for the radical cure of P. vivax malaria infection. Implementation of DOT reduces the reappearance rate of the parasite, and may subsequently decrease P. vivax transmission in the area. |
format | Text |
id | pubmed-2988041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29880412010-11-19 Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border Takeuchi, Rie Lawpoolsri, Saranath Imwong, Mallika Kobayashi, Jun Kaewkungwal, Jaranit Pukrittayakamee, Sasithon Puangsa-art, Supalap Thanyavanich, Nipon Maneeboonyang, Wanchai Day, Nicholas PJ Singhasivanon, Pratap Malar J Research BACKGROUND: Plasmodium vivax has a dormant hepatic stage, called the hypnozoite, which can cause relapse months after the initial attack. For 50 years, primaquine has been used as a hypnozoitocide to radically cure P. vivax infection, but major concerns remain regarding the side-effects of the drug and adherence to the 14-day regimen. This study examined the effectiveness of using the directly-observed therapy (DOT) method for the radical treatment of P. vivax malaria infection, to prevent reappearance of the parasite within the 90-day follow-up period. Other potential risk factors for the reappearance of P. vivax were also explored. METHODS: A randomized trial was conducted from May 2007 to January 2009 in a low malaria transmission area along the Thai-Myanmar border. Patients aged ≥ 3 years diagnosed with P. vivax by microscopy, were recruited. All patients were treated with the national standard regimen of chloroquine for three days followed by primaquine for 14 days. Patients were randomized to receive DOT or self-administered therapy (SAT). All patients were followed for three months to check for any reappearance of P. vivax. RESULTS: Of the 216 patients enrolled, 109 were randomized to DOT and 107 to SAT. All patients recovered without serious adverse effects. The vivax reappearance rate was significantly lower in the DOT group than the SAT group (3.4/10,000 person-days vs. 13.5/10,000 person-days, p = 0.021). Factors related to the reappearance of vivax malaria included inadequate total primaquine dosage received (< 2.75 mg/kg), duration of fever ≤ 2 days before initiation of treatment, parasite count on admission ≥ 10,000/µl, multiple P. vivax-genotype infection, and presence of P. falciparum infection during the follow-up period. CONCLUSIONS: Adherence to the 14-day primaquine regimen is important for the radical cure of P. vivax malaria infection. Implementation of DOT reduces the reappearance rate of the parasite, and may subsequently decrease P. vivax transmission in the area. BioMed Central 2010-11-01 /pmc/articles/PMC2988041/ /pubmed/21040545 http://dx.doi.org/10.1186/1475-2875-9-308 Text en Copyright ©2010 Takeuchi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Takeuchi, Rie Lawpoolsri, Saranath Imwong, Mallika Kobayashi, Jun Kaewkungwal, Jaranit Pukrittayakamee, Sasithon Puangsa-art, Supalap Thanyavanich, Nipon Maneeboonyang, Wanchai Day, Nicholas PJ Singhasivanon, Pratap Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border |
title | Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border |
title_full | Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border |
title_fullStr | Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border |
title_full_unstemmed | Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border |
title_short | Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border |
title_sort | directly-observed therapy (dot) for the radical 14-day primaquine treatment of plasmodium vivax malaria on the thai-myanmar border |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988041/ https://www.ncbi.nlm.nih.gov/pubmed/21040545 http://dx.doi.org/10.1186/1475-2875-9-308 |
work_keys_str_mv | AT takeuchirie directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT lawpoolsrisaranath directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT imwongmallika directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT kobayashijun directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT kaewkungwaljaranit directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT pukrittayakameesasithon directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT puangsaartsupalap directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT thanyavanichnipon directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT maneeboonyangwanchai directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT daynicholaspj directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder AT singhasivanonpratap directlyobservedtherapydotfortheradical14dayprimaquinetreatmentofplasmodiumvivaxmalariaonthethaimyanmarborder |